tirzepatide Mounjaro
Selected indexed studies
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. (JAMA, 2024) [PMID:38078870]
- New Drug: Tirzepatide (Mounjaro(™)). (Sr Care Pharm, 2023) [PMID:36751934]
- Tirzepatide for Obesity Treatment and Diabetes Prevention. (N Engl J Med, 2025) [PMID:39536238]
_Worker-drafted node — pending editorial review._
Connections
tirzepatide Mounjaro is a side effect of
Sources
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. (2024) pubmed
- Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. (2024) pubmed
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. (2024) pubmed
- Tirzepatide for Obesity Treatment and Diabetes Prevention. (2025) pubmed
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. (2023) pubmed
- Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. (2024) pubmed
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. (2025) pubmed
- New Drug: Tirzepatide (Mounjaro(™)). (2023) pubmed
- Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. (2024) pubmed
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. (2024) pubmed